financetom
Business
financetom
/
Business
/
Advanced Micro Devices' Analyst Day Should Give Clarity on MI450 Opportunity, Morgan Stanley Says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Advanced Micro Devices' Analyst Day Should Give Clarity on MI450 Opportunity, Morgan Stanley Says
Nov 5, 2025 8:29 AM

11:08 AM EST, 11/05/2025 (MT Newswires) -- Advanced Micro Devices ( AMD ) had a good quarter as expected, but all eyes are on its analyst day next week, which should give clarity on the value proposition of the MI450 rack scale and the benefits of the ZT Systems acquisition, Morgan Stanley said in a Wednesday note.

The company's overall financial results aligned with expectations except for gaming, which performed slightly better than anticipated, Morgan Stanley analysts said.

The server market remains strong, and AMD is driving strong value growth in PCs, the analysts said. They added that the embedded segment, which includes specialized computing applications, is expected to see a cyclical recovery with the company confirming growth next year.

On the artificial intelligence front, AMD returned to year-over-year growth in Q3 after declines in H1. The company is still "lackluster" compared to its peers, with Nvidia ( NVDA ) and Broadcom's ( AVGO ) Application-Specific Integrated Circuits growing much faster, according to the note.

The analysts said they project continued share gains in notebook and server processors in 2025 and 2026 as AMD continues to execute on its product roadmap. The company's core business should accelerate significantly, driven by the return of server upgrades and ongoing growth in the PC market, while conditions in gaming and embedded markets are anticipated to normalize.

AMD's AI business, particularly with new MI400 products, should gain momentum in 2026, but maintaining leadership in performance is critical for its success in the segment, the note said.

Morgan Stanley maintained the company's stock rating at equal-weight and raised the price target to $260 from $246.

Price: 247.33, Change: -2.72, Percent Change: -1.09

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Aurora Cannabis Up in U.S. Pre-Market After Swinging to Fiscal Q1 Profit
Aurora Cannabis Up in U.S. Pre-Market After Swinging to Fiscal Q1 Profit
Aug 7, 2024
07:53 AM EDT, 08/07/2024 (MT Newswires) -- Aurora Cannabis ( ACB ) swung to a profit in the first quarter, booking net income from continuing operations of $4.8 million, reversing a loss of $20.2 million. For the three months ended June 30, revenue increased 12% to $83.4 million, driven by record revenue of $47.2 million from the company's global medical...
New York Times' Q2 Adjusted Earnings, Revenue Rise
New York Times' Q2 Adjusted Earnings, Revenue Rise
Aug 7, 2024
07:52 AM EDT, 08/07/2024 (MT Newswires) -- New York Times ( NYT ) reported Q2 adjusted earnings Wednesday of $0.45 per diluted share, up from $0.38 a year earlier. Analysts polled by Capital IQ expected $0.41. Revenue for the quarter ended June 30 was $625.1 million, up from $590.9 million a year earlier. Analysts surveyed by Capital IQ expected $625.2...
Emerson's quarterly earnings rise on measurement instruments demand
Emerson's quarterly earnings rise on measurement instruments demand
Aug 7, 2024
Aug 7 (Reuters) - Emerson Electric ( EMR ) reported higher third-quarter earnings on Wednesday, aided by demand for its unit which makes valves, regulators and actuators. Emerson's measurement and analytical devices have continued to benefit from manufacturers and end customers across the chemical, oil and gas industries. The company however has pivoted its focus on automation products and services,...
Top Premarket Decliners
Top Premarket Decliners
Aug 7, 2024
07:54 AM EDT, 08/07/2024 (MT Newswires) -- Talis Biomedical ( TLIS ) shares slumped 47% pre-bell Wednesday after Tuesday's 2.5% gain. Emergent BioSolutions ( EBS ) shares fell 35% after reporting weaker Q2 financial results. National Vision ( EYE ) shares dropped 13% following a 2.6% gain in the previous session. Price: 4.75, Change: -4.26, Percent Change: -47.28 ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved